Dec. 23 at 7:36 AM
$CMMB
CM-101 is not a drug targeted at a single organ, but rather acts on a systemic fibrosis pathway throughout the body. The drug inhibits the CCL24 protein, a central signaling pathway responsible for initiating and maintaining fibrosis. This protein acts systemically and is involved in fibrosis of the liver, kidneys, lungs, skin, and organ transplants. Most other drugs target a specific organ or act downstream, while CM-101 blocks the signaling pathway at its source. Therefore, there is currently no direct competitor on the same therapeutic pathway. Drugs with this systemic and platform-based approach are often acquisition targets, not just entry points.
